Nice numbers at 20: what end-of-life evidence does NICE draw on?NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend Share XNice numbers at 20: what end-of-life evidence does NICE draw on?https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-what-end-of-life-evidence-does-nice-draw-on/
NICE numbers at 20: trends in dealsNICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends Share XNICE numbers at 20: trends in dealshttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/
NICE numbers at 20 – a closer look at cancerThere has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Share XNICE numbers at 20 – a closer look at cancerhttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-a-closer-look-at-cancer/
NICE’s track record in cancer drugs: the impact of the CDF and interim fundingLeela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 Share XNICE’s track record in cancer drugs: the impact of the CDF and interim fundinghttps://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/
NICE numbers at 20Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed Share XNICE numbers at 20https://pharmaphorum.com/views-analysis-market-access/nice-numbers-20/
